NewAmsterdam Pharma Co N.V.
For the period ended Jun 4, 2025. Filed May 8, 2025.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
Jun 4, 2025 · Filed May 8, 2025
NAMS$18.90+0.1%Stored close · as of Nov 6, 2026
Contents
Summary Compensation Table
The following table sets forth information required under SEC rules concerning the compensation paid to our NEOs in respect of fiscal years ended December 31, 2024 and 2023.
| Name and Principal Position | Year | Salary(1)($) | Bonus($) | OptionAwards(2)($) | Non-EquityIncentive PlanCompensation(3)($) | All OtherCompensation(4)($) | Total($) |
|---|---|---|---|---|---|---|---|
| Michael Davidson, M.D. | 2024 | 621,300 | 5,347,060 | 497,040 | 3,897 | 6,469,297 | |
| Chief Executive Officer | 2023 | 569,000 | 313,000 | 4,923,558 | 5,805,558 | ||
| Ian Somaiya | 2024 | 468,000 | 411,337 | 368,550 | 4,688 | 1,252,575 | |
| Chief Financial Officer | 2023 | 90,576 | 40,000 | 3,422,493 | 3,553,069 | ||
| John Kastelein, M.D., Ph.D. FESC | 2024 | 486,046 | 2,570,852 | 327,031 | 3,383,929 | ||
| Chief Scientific Officer | 2023 | 459,346 | 218,412 | 2,300,813 | 2,978,571 | ||
| Juliette Audet(5) | 2024 | 322,254 | 2,602,746 | 188,406 | 25,068 | 3,138,474 | |
| Chief Strategy and Business Officer | 2023 | ||||||
| Douglas Kling | 2024 | 499,968 | 1,664,729 | 399,974 | 13,800 | 2,578,471 | |
| Chief Operating Officer | 2023 | ||||||
| (1) | The U.S. dollar amount reported for 2024 for Dr. Kastelein from Euros using the 2024 average exchange rate of $1.0824 per EUR. The U.S. dollar amount reported for 2024 for Ms. Audet were converted from Swiss Francs (“CHF”) using the average exchange rate of $1.1337 per CHF during the 9-month period starting April 1, 2024, through December 31, 2024. |
| (2) | Represents the aggregate fair value of awards on the date they were granted in accordance with ASC Topic 718. See the Notes to the Consolidated Financial Statements included herein for the assumptions used to calculate grant date fair value. |
| (3) | The amounts reported are comprised of amounts paid in respect of our annual performance-based cash bonus plan, as determined by the Compensation Committee. Payments pursuant to the plan are generally made early in the year following the year in which they are earned. The U.S. dollar amount reported for 2024 for Ms. Audet were converted from CHF using the average exchange rate of $1.1337 per CHF during the 9-month period starting April 1, 2024, through December 31, 2024. |
| (4) | The amounts reported in this column represent the amount of fees Dr. Davidson received for service on the Board of Directors in 2024, the amounts of Company contributions under our 401(k) plan for Messrs. Somaiya and Kling, and the Company pension contribution for Ms. Audet. The Company pension contribution for Ms. Audet was converted from CHF to U.S. dollars using the average exchange rate of $1.1337 per CHF during the 9-month period starting April 1, 2024, through December 31, 2024. |
| (5) | Ms. Audet joined the Company as Chief Business Officer in April 2024. Her compensation included in the table above represents her pro-rata base salary and bonus and her initial equity award. The Company promoted Ms. Audet to serve as Chief Strategy and Business Officer in May 2025. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.